NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free VERA Stock Alerts $39.65 +0.96 (+2.48%) (As of 04/26/2024 08:53 PM ET) Add Compare Share Share Today's Range$38.40▼$40.2550-Day Range$37.41▼$49.1452-Week Range$6.07▼$50.78Volume856,700 shsAverage Volume1.28 million shsMarket Capitalization$2.16 billionP/E RatioN/ADividend YieldN/APrice Target$32.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vera Therapeutics alerts: Email Address Vera Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside18.6% Downside$32.29 Price TargetShort InterestBearish16.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$21.53 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.18) to ($2.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 starsMedical Sector825th out of 916 stocksBiotechnology Industry25th out of 33 stocks 1.5 Analyst's Opinion Consensus RatingVera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVera Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.07% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Vera Therapeutics has recently decreased by 0.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERA. Previous Next 2.0 News and Social Media Coverage News SentimentVera Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.Search InterestOnly 5 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold 330.67% more of their company's stock than they have bought. Specifically, they have bought $4,999,990.00 in company stock and sold $21,533,345.00 in company stock.Percentage Held by Insiders21.70% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -17.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -17.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 20.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Vera Therapeutics Stock (NASDAQ:VERA)Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Read More VERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERA Stock News HeadlinesApril 13, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of StockApril 8, 2024 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in StockApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 21, 2024 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from AnalystsApril 14, 2024 | investing.comVera Therapeutics executive sells over $228k in company stockApril 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | finance.yahoo.comInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...April 11, 2024 | msn.comBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 10, 2024 | msn.comAlpine Immune jumps on report of takeover interestApril 7, 2024 | nasdaq.comCommit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using OptionsApril 3, 2024 | seekingalpha.comVera Therapeutics: Waiting For A PullbackMarch 26, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Vera Therapeutics Ahead of Key Atacicept Clinical MilestonesMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics with Promising Trials and Strong Financial RunwayMarch 20, 2024 | benzinga.comVera Therapeutics: Q4 Earnings InsightsMarch 20, 2024 | msn.comVera Therapeutics GAAP EPS of -$2.25 misses by $0.07March 20, 2024 | investorplace.comVERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023March 20, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 17, 2024 | bbc.co.ukWeekend Woman’s Hour: Irish folk singer Cara Dillon, The Hampstead Paedophile Hoax, MaximalismMarch 16, 2024 | finance.yahoo.comVERA Mar 2024 17.500 callMarch 16, 2024 | ca.finance.yahoo.comVERA Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comVERA Apr 2024 50.000 putMarch 14, 2024 | morningstar.comVera Therapeutics Inc Class A VERAMarch 14, 2024 | finance.yahoo.comRWE CEO: no plans for big, transformative dealsMarch 13, 2024 | nbcnews.comThe best foot peels for soft, smooth skin, according to expertsMarch 12, 2024 | msn.comAre foot peels safe? Derms weigh inSee More Headlines Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:VERA CUSIPN/A CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$32.29 High Stock Price Target$56.00 Low Stock Price Target$22.00 Potential Upside/Downside-18.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.33% Return on Assets-50.79% Debt Debt-to-Equity Ratio0.49 Current Ratio7.71 Quick Ratio7.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book20.44Miscellaneous Outstanding Shares54,450,000Free Float42,636,000Market Cap$2.16 billion OptionableOptionable Beta1.05 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Marshall W. Fordyce M.D. (Age 49)Founder, President, CEO & Director Comp: $910.14kMr. Sean P. Grant M.B.A. (Age 39)Chief Financial Officer Comp: $642kMr. Joseph R. Young M.B.A. (Age 51)Senior VP of Finance & Chief Accounting Officer Mr. Julien E. Capers J.D.VP & Head of LegalMs. Kelly RauberVP & Head of Human ResourcesMr. Tom Doan (Age 52)Senior Vice President of Development Operations Ms. Lauren Frenz (Age 39)Chief Business Officer Dr. Neeraj Pakala M.B.A.Ph.D., Senior VP and Head of Product Development & ManufacturingDr. Kerry Cooper M.D.Senior Vice President of Medical AffairsDr. Robert M. Brenner M.D. (Age 56)Chief Medical Officer More ExecutivesKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTDyne TherapeuticsNASDAQ:DYNTG TherapeuticsNASDAQ:TGTXAvidity BiosciencesNASDAQ:RNAAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsJoseph R YoungSold 5,714 sharesTotal: $228,560.00 ($40.00/share)Sean GrantSold 99,828 sharesTotal: $3.95 M ($39.61/share)Maha KatabiSold 340,000 sharesTotal: $13.77 M ($40.50/share)Maha KatabiSold 81,009 sharesTotal: $3.58 M ($44.20/share)Kynam Capital Management LPBought 694,286 shares on 2/14/2024Ownership: 6.953%View All Insider TransactionsView All Institutional Transactions VERA Stock Analysis - Frequently Asked Questions Should I buy or sell Vera Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VERA shares. View VERA analyst ratings or view top-rated stocks. What is Vera Therapeutics' stock price target for 2024? 8 brokers have issued 12-month price targets for Vera Therapeutics' stock. Their VERA share price targets range from $22.00 to $56.00. On average, they predict the company's stock price to reach $32.29 in the next twelve months. This suggests that the stock has a possible downside of 18.6%. View analysts price targets for VERA or view top-rated stocks among Wall Street analysts. How have VERA shares performed in 2024? Vera Therapeutics' stock was trading at $15.38 at the beginning of 2024. Since then, VERA shares have increased by 157.8% and is now trading at $39.65. View the best growth stocks for 2024 here. When is Vera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VERA earnings forecast. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) issued its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.05. What ETFs hold Vera Therapeutics' stock? ETFs with the largest weight of Vera Therapeutics (NASDAQ:VERA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Invesco DWA SmallCap Momentum ETF (DWAS) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).iShares Micro-Cap ETF (IWC). When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERA) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
